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Abstract: Transfer RNA (tRNA) is subject to a multitude of posttranscriptional modifications which
can profoundly impact its functionality as the essential adaptor molecule in messenger RNA (mRNA)
translation. Therefore, dynamic regulation of tRNA modification in response to environmental
changes can tune the efficiency of gene expression in concert with the emerging epitranscriptomic
mRNA regulators. Several of the tRNA modifications are required to prevent human diseases and
are particularly important for proper development and generation of neurons. In addition to the
positive role of different tRNA modifications in prevention of neurodegeneration, certain cancer types
upregulate tRNA modification genes to sustain cancer cell gene expression and metastasis. Multiple
associations of defects in genes encoding subunits of the tRNA modifier complex Elongator with
human disease highlight the importance of proper anticodon wobble uridine modifications (xm5U34)
for health. Elongator functionality requires communication with accessory proteins and dynamic
phosphorylation, providing regulatory control of its function. Here, we summarized recent insights
into molecular functions of the complex and the role of Elongator dependent tRNA modification in
human disease.
Keywords: epitranscriptomics; tRNA; tRNA modification; Elongator; wobble uridine modifications;
U34; diphthamide; neurodegeneration; cancer
1. Epitranscriptomic Transfer RNA Regulation
Apart from the four standard nucleosides, cellular RNA contains a broad variety of
posttranscriptional modifications which may have significant impact on its function [1]. The total
RNA modification set of a cell is termed the epitranscriptome, and its dynamic changes are thought to
represent a strategy to modulate RNA function involving “writers” (modifiers), “erasers” (demodifiers)
and “readers”, proteins specifically recognizing RNA modifications [2,3]. Among the different types of
RNA subject to epitranscriptomic changes, transfer RNA (tRNA) harbors by far the most abundant
and chemically diverse modifications (Figure 1). While initially thought to be constitutively modified,
numerous examples are known by now demonstrating dynamic changes in tRNA modification
patterns in response to changing environments or conditions [4–13]. One of these involves a writer
methylase and an eraser demethylase, as observed in epitranscriptomic regulation of messenger
RNA (mRNA) translation [10]. In this case, mammalian ALKBH1 was identified as a demethylase
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removing the methyl-group in 1-methyladenosine (m1A), which is found in initiator and elongator
tRNAs and introduced by TRMT6 (substrate binding subunit) and TRMT61 (catalytic subunit) [10].
It was demonstrated that epitranscriptomic modulation of m1A presence in both tRNA types
(initiator and elongator) regulates tRNA function in translation initiation and elongation in a dynamic
manner in response to glucose availability [10]. Importantly, the absence of the eraser protein causes
embryonic lethality or neural defects in a mouse model system, indicating a direct or indirect role of
epitranscriptomic changes in mammalian tRNA for prevention of disease [10].
Despite the fact that m1A represents the only tRNA modification known so far to be actively
removed by an eraser protein, a variety of additional modifications are altered in their relative
abundance in response to changing environmental or physiological conditions. These triggers
include elevated temperature, oxidative stress or availability of nutrients required for synthesis
of modifications, e.g., sulfur, bicarbonate, queuine or taurine [4–6,9,11,13]. Due to the growing body
of evidence for a dynamic, rather than static nature of tRNA modifications, additional examples for
epitranscriptomic regulation of tRNA function should be envisioned.
Figure 1. Transfer RNA (tRNA) modifications associated with human disease. (A) Schematic
representation of a cytoplasmic tRNA with disease linked modifications at indicated base positions.
Modification genes linked to human diseases when mutated or upregulated are denoted (see Table 1 and
references therein for details). (B) Overview of steps and genes involved in xm5U34 synthesis. A broken
line between U34 and s2U34 indicates the fact that several lines of evidence support preferential action
of the thiolase on mcm5U34 rather than unmodified U34. Elongator specifies different subunits of the
Elongator complex, whereas thiolase represents the complex composed of subunits CTU1 and CTU2.
Abbreviations for U34 modifications are according to the modomics database [14].
2. Disease Related Transfer RNA Modifications
For tRNA to function as the adaptor molecule in translation, its folding into an L-shaped
structure is essential [1]. The structure is characterized by tertiary base-pairing and the presence
of stems formed by intramolecular base-pairing in addition to single-stranded loops. A number of
posttranscriptional modifications in unpaired tRNA loop regions contribute to tRNA structure by
preventing canonical base-pairing [15]. Not only cytoplasmic but also mitochondrial tRNA is subject
to dynamic modification by enzymes encoded in the nucleus [9,11]. A variety of human diseases are
linked to mutations in genes required for introduction of modifications [16–20] in both cytoplasmic
and mitochondrial tRNAs (Figure 1 and Table 1). Diseases associated with defects in human tRNA
modification genes include various neurological syndromes as well as metabolic and respiratory
dysfunctions (Table 1). In addition, an upregulation of different tRNA modification genes is observed
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in various cancer types (Table 1), suggesting an increased demand for the activity of tRNA modifiers
in different tumor cell types.
Table 1. Transfer RNA (tRNA) modification genes linked to human disease.
Disease Genes Modification
Familial dysautonomia 1 [21–23] IKBKAP mcm5(s2)U34, ncm5U34, ncm5Um34
Intellectual disability 1 [24,25] ELP2 mcm5(s2)U34, ncm5U34, ncm5Um34
Amyotrophic lateral sclerosis 1 [26,27] ELP3 mcm5(s2)U34, ncm5U34, ncm5Um34
Breast-, bladder-, colorectal-, cervix- and testicular cancer1 [28] hTRM9L * mcm5(s2)U34 (? *)
Urothelial cancer 2 [29] ALKBH8 mcm5(s2)U34
Asthma 1 [30] IKBKAP mcm5(s2)U34, ncm5U34, ncm5Um34
Melanoma 2,3 [31,32] ELP1, 3, 5, 6, CTU1/2 mcm5(s2)U34, ncm5U34, ncm5Um34
Invasive breast cancer 2,3 [33] ELP3, CTU1/2 mcm5(s2)U34, ncm5U34, ncm5Um34
X-linked mental retardation 1 [34] FTSJ1 Cm32, Gm34, yW37, ncm5Um34
MELAS (mitochondrial encephalomyopathy, lactic acidosis and
stroke-like episodes) 1 [11,35–37]
Mt-tRNA LeuUAA´, MTO1,
GTPBP3 τm
5U34 (mito)
MERRF (myoclonus epilepsy with ragged-red fibers) 1 [11,38] Mt-tRNA
Lys
UUU, MTO1, GTPBP3,
MTU1 τm
5s2U34 (mito)
Deafness associated with rRNA A1555G mutation 1 [39] MTU1 s2U (mito)
Acute infantile liver failure1 [40] MTU1 s2u (mito)
Neurodegeneration, Galloway-Mowat syndrome1 [41,42] YRDC, KEOPS, OSGEPL1 t6A37
MERRF-like syndrome 1 [9] YRDC, KEOPS, OSGEPL1 t6A37
Type 2 diabetes 1 [43,44] CDKAL1 ms2t6A37
Breast cancer 2 [45] TRMT12 wybutosine37
Intellectual disability 1 [46,47] PUS3 Ψ38/39
Intellectual disability 1, Microcephaly 1, aggressive behavior 1 [48] PUS7 Ψ13/35
Intellectual disability 1 [49] NSUN2 m5C34,48,49
Dubowitz-like syndrome 1 [50] NSUN2 m5C34,48,49
Noonan-like syndrome 1 [51] NSUN2 m5C34,48,49
Skin-, breast- and colorectal cancer 2,3 [52–54] NSUN2 m5C34,48,49
Intellectual disability 1 [55] ADAT3 I34
Encephalopathy and myoclonic epilepsy 1 [56] TRIT1 i6A/ms2i6A37
Lung- and breast cancer 1 [57–59] TRIT1 i6A/ms2i6A37
Intellectual disability 1 [24] TRMT1 m2,2G26
Primordial dwarfism 1 [60] METTL1/WDR4, TRM82 m7G46
PEPS 1 (Partial epilepsy with pericentral spikes) [61] TRMT44 Um44
Microcephaly 1 [62,63] TRMT10A m1G9
Intellectual disability and early onset diabetes 1 [64,65], epilepsy 1 [65] TRMT10A m1G9
Breast cancer 2 [66] TRMT2A m5U54
Mitochondrial Myopathy and Sideroblastic Anemia 1 (MLASA) [67] PUS1 Ψmultiple (mito)
1 Disease associated with mutation or downregulation of modification gene; 2 Disease associated with upregulation
of modification gene; 3: Depletion of modification enzyme impaired tumorigenicity or cancer cell viability; . A tRNA
methyltransferase activity of hTRM9L has not yet been demonstrated. In cases when modification genes are
involved in formation of specific parts of complex modifications, this is indicated by underlining the relevant part.
Modifications are abbreviated according to [14]. Mito: modification in mitochondrial tRNA.
Among disease-relevant modifications targeting cytoplasmic tRNA species, neurological
disorders appear to be most common. These include intellectual disability, familial dysautonomia (FD),
epilepsy and other syndromes. Interestingly, various mutations known to cause defects in different
tRNA modifications such as 5-methylcytosine (m5C), 5-methoxycarbonylmethluridine (mcm 5U),
5-methoxycarbonylmethyl-2-thiouridine (mcm5s2U), 5-carbamoylmethyluridine (ncm5U),
pseudouridine (Ψ) at positions 38/39 and 13/35, 1-methylguanosine (m1G), inosine (I) and
N2,N2-dimethylguanosine (m2,2G) are all associated with intellectual disability in humans (Table 1),
suggesting normal brain function and development to be particularly dependent on the presence of
these modifications.
Considering the position of critical modifications within the tRNA (Figure 1), a remarkable feature
is that many of the disease-relevant tRNA modifications are naturally found within the anticodon loop
and more specifically, at the wobble position (34) of the anticodon. Wobble base modification defects
in mitochondrial tRNAs are also linked to various myopathies and may also induce neurological
symptoms (Table 1) [19,20,37], highlighting the central role of wobble base modifications for normal
functioning of tRNA in the different cellular compartments. Modifications at the wobble position
are known to enable expanded base-pairing possibilities (inosine) [68] or to improve translational
fidelity and elongation by optimizing codon translation rates (mcm5s2U) [69–74]. Wobble uridine
modifications of the xm5U type (mcm5U, mcm5s2U and ncm5U; Figure 1B) belong to the most complex
tRNA modifications in terms of involved genes (Table 2) and pathways as well as with respect to
posttranslational modification of the tRNA modifier complexes themselves [66]. Multiple correlations
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of xm5U defects (Table 1) with human disease indicate this modification family to be of outstanding
relevance for human health and development (Figure 2).
Table 2. Yeast and human genes of the Elongator and ubiquitin related modifier 1 (Urm1) pathways.
See text for references. Parts of the modification in which individual genes are involved are underlined.
Yeast Gene Human Orthologs/Synonym Modifications
ELP1 ELP1/IKAP mcm5s2U; mcm5U; ncm5U; ncm5Um
ELP2 ELP2 mcm5s2U; mcm5U; ncm5U; ncm5Um
ELP3 ELP3 mcm5s2U; mcm5U; ncm5U; ncm5Um
ELP4 ELP4 mcm5s2U; mcm5U; ncm5U; ncm5Um
ELP5 ELP5 mcm5s2U; mcm5U; ncm5U; ncm5Um
ELP6 ELP6 mcm5s2U; mcm5U; ncm5U; ncm5Um
TRM9 ALKBH8, hTRM9L * mcm5s2U; mcm5U
TRM112 TRMT112 mcm5s2U; mcm5U
NFS1 NFS1 mcm5s2U
TUM1 TUM1 mcm5s 2U
URM1 URM1 mcm5s2U
UBA4 UBA4 mcm5s2U
NCS2 CTU1 mcm5s2U
NCS6 CTU2 mcm5s2U
* A direct demonstration of tRNA methyltransferase activity is missing for hTRM9L. Modifications are abbreviated
according to [14].
Figure 2. U34 modifications in human diseases. Scheme showing the “Janus headed” nature of the
Elongator complex that plays an important role in human health and disease. (Top) The pseudo-atomic
model of the fully assembled Elongator complex is shown in cartoon and transparent surface
representation (Elp1/orange, Elp2/yellow, Elp3/pink, Elp4/green, Elp5/blue, Elp6/brown).
Additional regulatory factors (Kti11-Kti14, left) and subsequent modifications (right) are indicated and
labeled (for further details, see text). (Bottom) The opposing roles of reduced or enhanced levels of cm5
modifications in neurodegenerative diseases and cancer are highlighted.
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3. Elongator Dependent Transfer RNA Modifications
In anticodons of a subset of tRNAs, modifications of wobble uridines (U34) require the activity of
the Elongator complex (for recent reviews, see [18,75,76]). Target tRNAs receiving Elongator dependent
modifications are tRNALysUUU, tRNAGlnUUG, tRNAGluUUC, tRNAArgUCU, tRNAGlyUCC, tRNASerUGA,
tRNAProUGG, tRNAThrUGU, tRNAAlaUGC and tRNALeuUAA [77,78]. Elongator is a multi-subunit
(Elp1–Elp6) protein assembly that was originally isolated from yeast in association with elongating
RNA polymerase II holo-enzyme [79,80] and hence implicated in mRNA transcription rather than
translation [78,81,82].
However, Elongator is now known to assemble into an active holo-dodecameric complex
[(Elp1–Elp6)2] that binds tRNAs with different subunits [83–88]. Accordingly, Elongator operates as
a tRNA modifier in a conserved pathway that is found in all three domains of life and shown to be
functionally exchangeable between eukaryotic model organisms [86,89–93]. In yeast, the complex
attaches to U34 from eleven different tRNA species 5-carboxy-methyl (cm5) groups [77,78], which in
concert with additional enzymatic U34 modifier cascades can be further converted to even more
composite modifications including (but not limited to) ncm5, mcm5 or mcm5s2 (see Figure 1B, [77,78]).
Formation of the cm5 side chain is directly catalyzed by Elp3, Elongator’s catalytic core subunit,
which carries binding domains for tRNA and acetyl-CoA and a radical SAM (S-adenosyl-methionine)
motif that coordinates an organometallic [4Fe–4S]SAM cluster shown to be crucial for U34 modification
in vivo [78,81,89,94]. In support of this notion, archaeal Elp3 from Methanocaldococcus infernus has
been shown to modify U34 in the anticodon loop of synthetic tRNAArgUCU substrates in vitro in a
radical SAM dependent reaction containing electron donor (Na2S2O4), SAM and acetyl-CoA [93].
Moreover, sophisticated insights into the basis and mechanism for Elongator’s tRNA modification
capacity have been recently provided through elegant structure-functional work on prokaryotic Elp3
from Dehalococcoides mccartyi and holo-Elongator from the yeast Saccharomyces cerevisiae [86–88,95–97].
In addition to the biochemical isolation of Elongator (see above), genetic screens aimed at isolating
yeast mutants that resist anticodon cleavage by zymocin, a U34 modification-dependent tRNase
ribotoxin, were also instrumental in identifying Elongator subunits and accessory proteins with roles
related to U34 modification and regulation [78,98–104]. Together with other strategies from many
independent research labs, these approaches collectively led to the identification of the U34 wobble
methylase complex (Trm9•Trm112) [101,105–107] and components of a pathway (Nfs1, Tum1, Uba4,
Urm1, Ncs2, Ncs6) for Elongator related U34 thiolation [99,101,108–116]. The methyltransferase (MTase)
activity of Trm9•Trm112 appears to depend on Elongator activity for the concerted formation of mcm5
and mcm5s2 in yeast and related modifications by homologs of wobble methylase (ALKBH8•TRMT112)
in higher eukaryotic systems [117–120]. Intriguingly, Trm112 not only promotes the MTase activity of
the catalytic Trm9 subunit but also acts as an activating hub or platform for three more SAM-dependent
MTases modifying ribosomal RNA (Bud23), tRNA (Trm11) or eRF1 translation termination factor
(Mtq2) [121,122]. Collectively, this illustrates the importance of methyltransferases for mRNA
translation and de novo protein biosynthesis.
As for U34 thiolation and formation of the mcm5s2 modification, it has been shown that
S-incorporation into U34 substrate tRNAs by yeast wobble thiolase (Ncs2•Ncs6 aka CTU1•CTU2,
see Figure 1) requires a conserved S-relay system (Nfs1, Tum1, Uba4) for S-activation, S-mobilization
and S-transfer onto Urm1, a ubiquitin related modifier protein [109–114]. Urm1 is unique in
combining features typical of prokaryotic S-carriers with eukaryotic ubiquitin proteins [123,124].
In line with this notion, Urm1 can act as a non-canonical, lysine-directed protein modifier in
a pathway known as protein urmylation and as a sulfur donor for U34 thiolation [112–114,125].
Both roles are strictly sulfur-dependent and exchangeable among eukaryotes [115,116,126] and based
on Urm1-like proteins from archaea and bacteria [127,128]; they appear to be conserved and important
in all domains of life. In line with this, their inactivation triggers stress-induced growth defects in
microbes, organ underdevelopment in plants and, strikingly, lethality in flies [108,113,124,129–131].
In contrast to ubiquitin activation and conjugation by conventional E1-E2-E3 enzyme cascades,
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no E2/E3 activities for Urm1 are known to this end, and Urm1 activation by its E1-like enzyme
Uba4 results in C-terminal thiocarboxylation (Urm1-COSH) that is crucial for both urmylation and
tRNA thiolation [113,115,123,132,133].
The formation of Urm1-COSH is very similar if not identical to E1-like (MoeB or ThiF) activation
of bacterial S-carrier proteins (MoaD or ThiS) that (rather than being involved in protein conjugation)
solely donate sulfur for synthesis of molybdopterin or thiamine co-factors [134,135]. Thus, apart
from its similarity to eukaryotic ubiquitin-like proteins, Urm1 indeed relates to prokaryotic S-carrier
proteins, which is why the protein was coined a molecular fossil at the cross-road of protein
and RNA modifications [123]. Its dual-functionality requires desulfurase Nfs1, which mobilizes
sulfur from cysteine for direct S-transfer onto Uba4 [110,111] or indirectly via sulfur transferase
Tum1 [109,112–114]. Uba4 is equipped with MoeB-like (MoeBD, see above) and rhodanese-type
domains (RHD) that carry thiol-active cysteines [113,133]. S-transfer to the one in RHD results in a
persulfide, which, following adenylation of Urm1 by the MoeBD, likely forms an acyl-disulfide with the
Urm1 modifier [132,133,136]. Upon reductive cleavage of this bond, Urm1-COSH gets released [137]
to be able to operate in urmylation or donate the activated sulfur species for S-insertion into tRNAs by
thiolase Ncs2•Ncs6 [115,133]. Recently, in eukaryotic Ncs6 and TtuA (a related thiouridine synthetase
from thermophilic bacteria and archaea) [3Fe-4S] and [4Fe-4S] clusters were identified, respectively,
that appear to be involved (directly or indirectly) in the thio-modification reaction required for
s2U formation.
Together with findings that tRNA thiolation is apparently not required for protein urmylation
and vice versa, the two URM1 pathway branches—albeit mechanistically linked through sulfur
activation—seem to be functionally separated from rather than dependent on each other [115].
Thus, a previously suggested concept, according to which the sulfur flow from Urm1-COSH to
tRNA thiolation may be kept in-check by urmylation [138], seems less likely to date. However, in
this context, it is noteworthy that human URM1 (hURM1) and Urm1-like proteins (SAMP, TtuB) have
been shown to form urmylated conjugates with human and prokaryotic orthologs of yeast thiolase
(CTU1, CTU2, NcsA, TtuA) [125,127,128]. Whether or not this implies that S-transfer (via Urm1-COSH)
for tRNA thiolation may involve direct urmylation of thiolase subunits is unknown but attractive to
support the option of interdependence among the two URM1 pathway branches, protein urmylation
and U34 thiolation. Although the S-donor role of Urm1 for tRNA thiolation has been demonstrated
in vitro [137], we are not aware of sulfur transfer during lysine-directed urmylation of protein targets
(including thiolase components, see above) in yeast or other model organisms. Nonetheless, it has been
shown in human cell lines that IKAP (the homolog of yeast Elongator subunit Elp1) was urmylated
under conditions of oxidative stress [116]. Additional urmylation target proteins, including human
thiolase subunits CTU1 and CTU2 (see above) have been suggested as well [125]. Since the relevance
of IKAP urmylation for Elongator’s U34 modification function in human cells has not been addressed
and a functional link (if any) between urmylation of IKAP/Elp1 and thiolase (CTU1•CTU2) is not
clear for the time being, these intriguing phenomena remain to be resolved in the future.
4. U34 Modifications and Neurodegeneration
Notably, neurons are known to be particularly sensitive to translational defects for some time [139];
however, it was only recently shown that tRNA modifications in combination with the specific usage
of AA-ending over AG-ending codons fine tune the translation of specific neuronal transcripts [140].
In addition, a single point mutation in the Elongator subunit Elp6 was identified in a novel cerebellar
ataxia mouse model that triggers the cell type specific degeneration of Purkinje neurons [141].
The neuronal decay is accompanied by proteotoxic stress and substantial microgliosis, which can be
partially delayed by blocking the NLRP3 inflammasome. The Elp6 mutation leads to a destabilization
of the Elp456 subcomplex and reduces the tRNA modification levels [141] in a similar extent as FD
patients carrying Elp1 mutations (Table 1) [21].
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These similarities indicate that a certain reduction of modification levels causes severe cellular
malfunctions, whereas more dramatic alterations would not permit the survival of the patients.
Additionally, patients of sporadic amyotrophic lateral sclerosis (ALS) show reduced levels of Elp3
protein and mcm5s2U in the motor cortex [27]. The authors of this study further demonstrated
that the role of Elp3 in the pathogenesis of ALS is mediated through its tRNA modification
activity, which provided yet another link between tRNA modification defects and neurodegeneration.
However, the study surprisingly reported that the SAM domain of Elp3 seemed sufficient to rescue
the effects. This observation is in stark contrast to biochemical [86,93] and functional [69,89]
studies, showing that both the SAM and acetyl-CoA binding domains are necessary for Elp3’s
tRNA modification activity (see above). In summary, the list of neurodegenerative diseases that
are directly and indirectly connected to the disruption of the Elongator tRNA modifier complex is
continuously growing.
5. A Role of Protein Aggregation in Neurodegeneration
Using ribosome profiling, the absence of mcm5s2U in yeast tRNAGlnUUG and tRNALysUUU was
shown to result in a translational slow down at cognate glutamine and lysine codons [70]. This defect
goes hand-in-hand with the accumulation of cellular protein aggregates [70]. While the direct
mechanism of aggregate formation remains to be solved, a striking observation was that a large
overlap exists between aggregates induced by tRNA hypomodification and those formed in the
absence of a functional ribosome associated chaperone complex (ssb1/ssb2) [70,142]. This may indicate
that ribosomal slow down perturbs folding of the nascent polypeptides. Genetic approaches in budding
yeast further support that formation of protein aggregates in the absence of different important tRNA
modifications represents a key trigger of pleiotropic cellular defects in cell polarity, morphogenesis
and nuclear segregation during cell division [143].
Importantly, protein aggregation in the absence of U34 modification is not limited to the yeast
model system but was also observed in nematodes, mice and human cells [27,32,33,70,144,145].
In addition, the absence of the mitochondria-specific taurine-derived wobble uridine modifications
induce aggregation of mistargeted mitochondrial proteins [146]. Interestingly, protein aggregation
is also a hallmark of various neurodegenerative diseases, and therefore, might represent a
functional link between tRNA modification defects (affecting mcm5s2U and other modifications) and
neurodegenerative or neurodevelopmental diseases. In support of this, it was already demonstrated
that a conditional ELP3 knockout in mice induced the unfolded protein response (UPR) and
caused reduced numbers of cortical projection neurons, leading to neurodevelopmental defects and
microcephaly [144]. While UPR induction in tRNA modification mutants seems to be confined to
higher eukaryotic cell systems, aggregation of endogenous cytoplasmic proteins is observed in both
mammals and yeast cells [27,32,33,70,144,145,147].
Since mutations in ELP3 are also linked to the fatal degenerative motor neuron disorder ALS
(see above and Table 1), protein aggregation in a mouse motor neuron-like cell line was also analyzed.
Upon depletion of ELP3 from this cell line, protein aggregation including the ALS relevant mutant form
of SOD1 was observed [27]. In addition, several lines of evidence indicated the neurodegenerative
effects of the ELP6 mutation causing ataxia-like syndromes in a mouse model (see above) to be
accompanied by protein aggregation [141]. Additionally, silencing of either ELP3 or CTU2 (s 2U) in
human melanoma cells resulted in the induction of endogenous protein aggregates [32], suggesting
the effect of Elongator and tRNA thiolation defects on protein solubility to be general and highly
likely disease relevant. In the latter case, it was also observed that a key factor reprogramming cancer
cell gene expression (see below) depends on wobble uridine modification for efficient translation
and is present in the endogenous aggregates [32]. This observation is consistent with the proposal
that reduced codon translation rates in the absence of mcm5s2U cause protein folding defects and
aggregation of the nascent polypeptide. The finding that protein aggregation may also be induced
in yeast by defects in other modifications, such as Ψ38/39 or t6A [143,148] and that the very same
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defects in human cells cause related neurodegenerative/neurodevelopmental syndromes [41,47,60]
provide solid support for the assumption that protein aggregation may represent an important trigger
of neurodegenerative disease correlated with mutations in tRNA modifiers.
6. U34 Modification in Cancer
In addition to their roles in prevention of neurodegeneration, enzymes introducing U34 tRNA
modifications were also identified as key factors to sustain metastasis of breast and bladder cancer and
survival of malignant melanoma cells [32,33,149]. It has been known for some time that genes in DNA
damage repair pathways display a certain codon-bias [130,150] and that loss of Elongator or related
pathways (e.g., Uba4,Urm1, see above) can induce DNA damage [151]. This knowledge has recently
been extended by showing that the very same pathways are crucial determinants for the survival
of therapy-resistant melanoma cells. In detail, BRAFV600E is the most prevalent mutation among
human melanoma patients and responsible for resistance to targeted therapy. ELP1, ELP3, CTU1 and
CTU2 are strongly upregulated in BRAFV600E cells and inactivation of ELP3 impaired the development
of BRAFV600E melanoma in a zebrafish model [32]. Moreover, it was shown that the Elongator
complex promotes glycolysis in melanoma cells through direct, codon-dependent, regulation of the
translation of Hypoxia Induced factor 1 α (HIF1A) mRNA, and the maintenance of high levels of HIF1α
protein providing strong resistance to anti-BRAF therapy [32]. In a previous study the migration and
tumorigenicity of melanoma-derived cells was shown to be significantly decreased upon depletion of
ELP1, ELP3, ELP5 or ELP6 in melanoma cells [31]. In another study, ELP3 was shown to be upregulated
in human hepatocellular carcinoma (HCC) cells, which correlated well with the phosphorylation of
protein kinase B (AKT) [152]. The Elongator mediated migration and invasion of HCC cells is further
promoted by the induced expression of MMP-2 and MMP-9 through the PI3K (phosphoinositide
3-kinase)/AKT signaling pathway. ELP3 was also shown to drive Wnt-dependent tumor initiation
and regeneration in the intestine by maintaining a subpopulation of cells expressing LGR5- and SOX9
cells [153]. Furthermore, genetic ablation of ELP3 strongly impaired invasion and metastasis formation
in a model system of invasive breast cancer. In detail, ELP3 and CTU1•CTU2 are upregulated in human
invasive breast cancer and support cellular invasion through the translation of the DEK oncoprotein,
which subsequently promotes the IRES (internal ribosome entry site)-dependent translation of the
pro-invasive transcription factor LEF1 [33]. In addition, ALKBH8, the methyltransferase implicated in
the final step of mcm5s2U and mcm5U formation (Figure 1) is highly expressed in bladder cancer and
ALHBH8 knockdown induces cancer cell death due to reduced expression of the anti-apoptotic protein
survivin [29,149].
Hence, multiple lines of evidence indicate U34 modifications to promote cancer cell growth and
metastasis by ensuring efficient translation reprograming upon transition from normal to cancer cell
growth mode. In addition to upregulation of Elongator, ALKBH8 and thiolase genes CTU1 and CTU2
genes, other tRNA modification genes, including NSUN2 (m5C) and METTL1 (m 7G) also become
overexpressed in human cancers [52,54,154,155] (Table 1). Moreover, the latter two genes are implicated
in resistance against anti-cancer therapy [156] since NSUN2 upregulation is correlated with poor
prognosis in patients with in Head and Neck Squamous Carcinoma [157]. Changes in epitranscriptomic
tRNA modification in cancer cells may have a general broad significance for prognosis of disease
progression and therapy. Hence, a greater understanding of the underlying pathways involved in
the modification of U34 is necessary to further understand its two-faced character in human diseases.
It remains to be shown if a specific inhibitor for Elongator can be identified and developed. First and
foremost, a targeted therapy against Elongator must define a therapeutic window that permits the
treatment of cancer cells and simultaneously avoids negative effects on neuronal tissues.
7. Phosphoregulation of Elongator Involving Kti12 and Kti14/Hrr25
Several studies in yeast and other model organisms have shown that tRNA modifications,
including Elongator dependent ones can change in response to cell cycle progression and different
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environmental stresses. This indicates that tRNA modifications are subject to regulation rather than
being constitutively formed [158–160]. In case of the Elongator complex from yeast, several accessory
proteins have been described that influence its tRNA modification activity, namely Kti11-Kti14/Hrr25
and Sit4 (Figure 2). Consistent with this, a casein kinase 1 (CK1) isozyme (Kti14/Hrr25), type 2A
protein phosphatases (Sit4·Sap185 and Sit4·Sap190) and an Elongator interactor (Kti12) were shown to
affect the phosphorylation state of Elongator’s largest scaffold subunit Elp1 [98,161–163]. In principle,
dynamic phosphorylation may have an impact on Elongator’s catalytic Elp3 subunit, its localization or
its ability to interact with substrate tRNAs [164–166]. Although it is unclear what precise role Elp1
phosphorylation plays, it has been proposed as an ‘on/off’ switch for Elongator’s U34 modifier activity,
for example, in response to growth conditions or cellular stress. Given that translation of some mRNAs
are indeed dependent on proper U34 modification, and hence tunable by Elongator [130,167,168],
and that tRNA modifications including Elongator-dependent ones do oscillate, this raises the option
that Elongator is part of a translational control mechanism which functions through its role as a
U34 modifier. Such a role, which reflects that Elp1 phosphorylation by casein kinase Kti14/Hrr25
is largely positive for Elongator’s performance, is consistent with loss-of-function phenotypes
associated with kinase-dead hrr25/kti14 mutations, ablative Elp1 phosphosite substitutions and
specific inhibition by ATP analogs of an analog-sensitive Hrr25 kinase variant (Hrr25-I82G) [164,165].
Although Hrr25 operates on many cellular functions [169], which complicates providing clear
insights into Elp1 phosphorylation signals, its kinase activity is required for full functionality of
ribosomes and U34 containing tRNAs demonstrating its importance in mRNA translation and protein
synthesis [164,165,170–172]. Since dynamic IKAP/Elp1 phosphorylation was also observed in human
melanoma cells [32] and change in response to insulin availability, pharmacological interference with
this process may represent an attractive option to downregulate the Elongator function and possibly
impair cancer cell proliferation.
A key component in the phosphoregulation of Elp1 seems to be the Elongator partner protein
Kti12 (Figure 2). Although the precise role of Kti12 is ill-defined, the yeast protein and its plant
ortholog (DRL1/ELO4) carry N-terminal P-loop motifs that are typical of nucleotide binding kinases
and NTPases [173–177]. Consistent with a functional role for this domain, a P-loop truncation triggers
defects typical of Elongator mutants including loss of U34 modification [98]. Importantly, Kti12 interacts
with the Hrr25 kinase in an Elongator-dependent fashion and in doing so, apparently supports
Elp1 phosphorylation [98,100,102,178]. This is based on data showing that KTI12 gene deletions
abolish Elongator interaction with Hrr25, cause U34 modification defects typical of elp (and hrr25)
mutants and trigger formation of hypo-phosphorylated Elp1 isoforms similar to kinase-dead hrr25
cells [101,161,165].
8. Elongator Regulation via Kti11/Dph3 and Kti13
Two additional factors involved in Elongator regulation are Kti11 (alias Dph3) and Kti13
(alias Ats1) [179] (Figure 2). Kti11 precipitates Elongator subunits (Elp1, Elp2, Elp3, Elp5) and associates
with Kti13 [108,180,181] in a hetero-dimer shown not only to affect Elongator’s U34 modification
activity but also to relate to a posttranslational protein modification pathway [108,180–184].
The Kti11/Dph3•Kti13 complex has been implicated in electron transfer to Elp3 for radical
SAM dependent U34 modification by the Elongator complex [182,183]. Removal of Kti11
(i.e., no electron flow) was found to eliminate the U34 modifier activity of Elongator while loss of
Kti13 significantly reduced the tRNA modification function to ~20% of wild-type levels [78,180,181].
Kti11/Dph3 partakes together with Dph1, Dph2, Dph4, Dph5, Dph6 and Dph7 in the synthesis of
diphthamide, a posttranslationally modified histidine residue (His699 in yeast; His715 in humans)
found on translation elongation factor 2 (EF2) [185,186]. EF2 is an essential translation factor
that mediates the translocation of the ribosome on the mRNA during translation elongation.
Strikingly, diphthamide modified EF2 is the target for diphtheria toxin (DT), which inactivates
the translation factor via ADP (adenosine diphosphate)-ribosylation, and thereby, induces death
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of the intoxicated cell [187–189]. Thus, the absence of Dph3/Kti11 leads to full resistance to the
lethal ADP-riboslyase activity of DT [180,182,185,186,190]. These data clearly indicate a pathological
role for the diphthamide modification in cell growth and proliferation control. The physiological
relevance of diphthamide-modified EF2 is less evident [191,192]. However, recent functional and
structural analyses suggest diphthamide-modified EF2 supports reading frame maintenance and
reduces ribosomal errors [190,193–197].
Based on structure-function analyses, Kti11/Dph3 carries a metal (iron, zinc) binding
domain [182,183,198] that is essential for both the modification of U34 carrying tRNAs by Elongator
and the synthesis of diphthamide on EF2 [182,183]. Similar to bacterial rubredoxins, Kti11/Dph3 is
a redox-active protein and capable of electron transfer to the iron-sulfur clusters of Elongator’s core
subunit Elp3 [86,89] and the radical SAM enzyme Dph1•Dph2, which is essential for the first step
of diphthamide biosynthesis [108,180,186,199]. Dong et al. (2014) reconstituted a reaction in vitro,
in which Dph3/Kti11 was able to feed electrons into the [4Fe–4S]SAM cluster of the Dph1•Dph2 enzyme
for reductive SAM cleavage and generation of a 3-amino-3-carboxypropyl radical (ACP) subsequently
used for formation of ACP-EF2, the first intermediate of the diphthamide pathway [200–203].
Moreover, the Dph3/Kti11 reductase Cbr1 has been identified, which is required for recycling the
electron carrier and transfer function of Dph3/Kti11 to both the U34 and the diphthamide modification
pathways [204].
The formation of a stable Kti11/Dph3•Kti13 heterodimer suggested an involvement of not only
Kti11, but also Kti13 in diphthamide formation [181–183]. Indeed, a yeast KTI13 gene deletion strain
was shown to confer protection against growth inhibition by DT (see above) [182]. Apart from
Kti11/Dph3 and Cbr1, Kti13 may, therefore, be yet another factor operating in both the radical SAM
pathways for Elongator dependent tRNA modification and diphthamide synthesis on EF2 [182,183].
Table 3. Diphthamide synthesis genes and defects linked to disease syndromes in higher eukaryotes.
Gene
Elongation
factor 2 (EF2)
Modification
xm 5U34
Modification
Species Disease/Syndrome
DPH1 absent present Human
Lung cancer [205]
Breast cancer [206,207]
Brain tumors [208]
Ovarian cancer [209,210]
Colorectal cancer [211]
Intellectual disability and craniofacial abnormalities [212,213]
Miller-Dieker syndrome (MDS) [214]
Airway obstruction and external genital abnormalities [215]
Mouse Embryonic lethal, cell proliferation defect, edema, polydactyly [216]Embryonic jaw shortening, cleft palate [214]
Fruit fly Failure of intestinal stem cell proliferation [217]
KTI11/DPH3 absent absent Chinesehamster Reduced life span hunder [218]
Mouse Necrosis, apoptosis and defects in development of placenta [219]
DPH4 absent present Mouse Neuronal underdevelopment, impaired growth and polydactyly [220]
DPH5 absent present Fruit fly Intestinal stem cell defect [217]
Table 1 lists up severe pathologies in humans that are linked with Elongator dependent
and related tRNA modification defects. Similarly, defects in genes involved in the diphthamide
synthesis pathway of higher eukaryotic model organisms can associate with a variety of diseases
and syndromes (Table 3) such as tumorigenesis [205–211], intellectual disability, craniofacial
abnormalities [212,213] and Miller-Dieker Syndrome (MDS) [214], as well as airway obstruction and
external genital abnormalities [215] in humans. In mice, embryonic lethality, edema, polaydactyly, jaw
shortening, cleft palate, necrosis, apoptosis and defects in placenta development as well as neuronal
underdevelopment have been observed in conjunction with diphthamide defects [214,216,219,220].
Furthermore, sensitivity to oxidative stress was reported in chinese hamsters to correlate with failure to
diphthamide-modify EF2 [218]. Moreover, failure of intestinal stem cell proliferation has been strictly
associated with malfunctional Dph1 and Dph5 in Drosophila melanogaster [217]. Hence, defects in both
the radical SAM pathways for tRNA and EF2 modifications, which have been shown to interfere with
the fidelity and efficiency of mRNA translation elongation and trigger ribosomal errors, are potentially
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linked to a multitude of diseases (Table 1 and 3) from several eukaryotes. With the Kti11/Dph3•Kti13
heterodimer and the Cbr1 reductase qualifying as prime candidates to interconnect and possibly,
cross-link U34 and diphthamide modifications, there is the emerging prospect for regulation of disease
related radical SAM modifier enzymes by a common mechanism that involves control by electron flow
to (and from) their iron-sulfur centers. Further studies will be required to address whether drug-based
interference with Kti11/Dph3•Kti13 and/or Cbr1 functioning may provide new intervention schemes
against disease syndromes linked with dynamic changes of epitranscriptomic tRNA modifications
typical of defects in Elongator or the related diphthamide synthesis pathway.
9. Conclusions
tRNA modifications are required for optimal translational efficiency and fidelity. A growing list
of dynamic tRNA modifications suggests a role in adaptation of translational efficiency to changes
in environmental conditions. Consequently, several of these modifications are necessary to prevent
human disease. Among the diseases linked to modification/modifier defects, neurodevelopmental
syndromes are common, pointing to a specific requirement of full tRNA modification sets in
neuronal cells. Among the different modifications linked to human disease, wobble uridine
modifications dependent on the Elongator complex are prevalent. Elongator dependent tRNA
modifications are not only required for human brain cell function, but also for cancer cell function.
Recent work strengthens the implication of Elongator dependent tRNA modifications in sustaining
metastasis and uncovered potential regulatory inputs into the modifier complex. Further work will be
required to determine whether drug-based interference with Elongator function or regulation opens
new approaches to cancer therapy.
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